BIOVENTUS CLASS A INC (BVS)
Health Care · Orthopedic medical devices and regenerative medicine · NASDAQ
Bioventus is an orthopedic medical technology company focused on pain relief and musculoskeletal treatment through hyaluronic acid viscosupplements, bone growth stimulators, and emerging surgical and regenerative medicine platforms.
What BIOVENTUS CLASS A INC does
Bioventus is a diversified orthopedic medical technology company that develops and commercializes products for pain management and musculoskeletal care across multiple treatment modalities. The company's portfolio spans hyaluronic acid viscosupplements for osteoarthritis, bone growth stimulation devices, fracture care solutions, peripheral nerve stimulation, platelet-rich plasma systems, and ultrasonic surgical platforms. Products are distributed through direct sales and international channels to physicians, ASCs, and hospitals across pain treatments, surgical solutions, and restorative therapies.
Themes: ["Orthopedic pain management","Osteoarthritis treatment","Bone growth stimulation","Surgical instrumentation / ultrasonic technology","Peripheral nerve stimulation","Regenerative medicine / PRP","International expansion"]
Fundamentals
- Price$12.22 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return+66.9% as of 2026-07-09 close
- P/E35.84 as of 2026-07-10
- Net margin+4.9% as of 2026-07-10
- Gross margin+68.7% as of 2026-07-10
- ROE+16.3% as of 2026-07-10
- Debt / equity1.49 as of 2026-07-10
- Revenue growth (YoY)+1.5% as of 2026-07-10
- Revenue CAGR (3y)+3.5% SEC XBRL
- Beta0.71 as of 2026-07-10
Key risks (from latest filing)
["Dependence on limited core product portfolio (HA, BGS, fracture care) for majority of sales; long-term growth dependent on successful development and commercialization of new products","Regulatory uncertainty including FDA's proposed down-classification of bone growth stimulators (EXOGEN), which could increase competition; clinical trial failures could prevent product expansion","Pricing and reimbursement pressure from government healthcare cost-containment initiatives and potential impact from tariffs, trade barriers, and supply chain disruptions"]
Competitors & peers
- Zimmer Biomet
- Stryker Corporation
- Smith & Nephew
- Arthrex
- Serica Technologies
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.